Wall Street analysts expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to announce sales of $361.96 million for the current quarter, according to Zacks. Six analysts have provided estimates for Integra Lifesciences’ earnings, with the highest sales estimate coming in at $370.70 million and the lowest estimate coming in at $359.03 million. Integra Lifesciences posted sales of $357.08 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 1.4%. The company is expected to issue its next earnings report on Wednesday, April 24th.
According to Zacks, analysts expect that Integra Lifesciences will report full-year sales of $1.52 billion for the current financial year. For the next financial year, analysts forecast that the company will post sales of $1.60 billion, with estimates ranging from $1.59 billion to $1.61 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, February 21st. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.03. Integra Lifesciences had a return on equity of 16.02% and a net margin of 4.13%. The business had revenue of $383.30 million during the quarter, compared to analyst estimates of $382.33 million. During the same period in the previous year, the firm earned $0.64 EPS. Integra Lifesciences’s quarterly revenue was up 4.0% compared to the same quarter last year.
NASDAQ:IART opened at $56.14 on Tuesday. Integra Lifesciences has a twelve month low of $42.14 and a twelve month high of $67.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.95 and a quick ratio of 1.88. The company has a market cap of $4.72 billion, a price-to-earnings ratio of 23.20, a PEG ratio of 1.63 and a beta of 0.96.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of Integra Lifesciences by 5.7% in the 4th quarter. Geode Capital Management LLC now owns 731,431 shares of the life sciences company’s stock valued at $32,987,000 after buying an additional 39,637 shares during the last quarter. Norges Bank acquired a new stake in shares of Integra Lifesciences in the 4th quarter valued at approximately $32,141,000. O Brien Greene & Co. Inc acquired a new stake in shares of Integra Lifesciences in the 4th quarter valued at approximately $410,000. Executive Wealth Management LLC acquired a new stake in shares of Integra Lifesciences in the 4th quarter valued at approximately $38,000. Finally, Amalgamated Bank boosted its holdings in shares of Integra Lifesciences by 42.7% in the 4th quarter. Amalgamated Bank now owns 16,096 shares of the life sciences company’s stock valued at $726,000 after buying an additional 4,813 shares during the last quarter. 83.11% of the stock is owned by institutional investors.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.